Stevanato Group Reports Q3 2026 Revenue Growth Amid Shifting GLP-1 Demand
Stevanato Group S.p.A. (STVN) reported third-quarter revenue of EUR 326.1 million, marking an 8% organic growth rate driven largely by its Biopharmaceutical and Diagnostic Solutions segment. The company saw a significant 14% year-over-year increase in adjusted EBITDA to EUR 88.8 million, with margins expanding by 150 basis points to 27.2%. Despite the strong quarterly performance, management issued a cautious outlook for fiscal 2027, citing anticipated lower volumes for GLP-1 medications from a key customer which will moderate growth to low single digits. While full-year 2026 guidance was reiterated, the Engineering segment faced headwinds due to order delays and declining sales in pharma visual inspection.
Topics: Adjusted EBITDA Fiscal Guidance GLP-1 Revenue Share Revenue Growth